RESUMO
A total of 220 adults and children > 10 years old (mean 29.5 +/- 11.7 years) with pharyngitis/tonsillitis were randomized to receive either cefpodoxime proxetil 100 mg bid for 5 days (n = 113) or phenoxymethyl penicillin, 600 mg tid for 10 days (n = 107). At the end of treatment of the 166 evaluable patients, a satisfactory clinical response was obtained in 85/88 (96.6%) patients treated with cefpodoxime proxetil and in 75/78 (96.1%) treated with phenoxymethyl penicillin. Group A beta-hemolytic streptococci (GABHS) eradication was similar in both groups: 79/82 (96.3%) patients in the cefpodoxime proxetil group and 64/68 (94.1%) patients in the phenoxymethyl penicillin group. At follow-up (20-30 days after the end of treatment) the GABHS eradication persisted in 67/72 (93.1%) patients treated with cefpodoxime proxetil and in 56/61 (91.8%) patients treated with phenoxymethyl penicillin. Significantly better compliance (p < 0.01) was noticed with the cefpodoxime proxetil regimen compared with the phenoxymethyl penicillin regimen, with only 2/110 (2%) poorly compliant patients in the cefpodoxime proxetil group vs 17/104 (16%) in the phenoxymethyl penicillin group. Thus, the shorter duration of therapy, in conjunction with demonstrated clinical and bacteriological efficacy that is equivalent to standard therapy, makes cefpodoxime proxetil an acceptable alternative for the treatment of GABHS pharyngitis/tonsillitis.
Assuntos
Ceftizoxima/análogos & derivados , Penicilina V/administração & dosagem , Faringite/tratamento farmacológico , Pró-Fármacos/administração & dosagem , Infecções Estreptocócicas/tratamento farmacológico , Streptococcus pyogenes , Tonsilite/tratamento farmacológico , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Ceftizoxima/administração & dosagem , Ceftizoxima/uso terapêutico , Criança , Esquema de Medicação , Feminino , França , Humanos , Masculino , Pessoa de Meia-Idade , Penicilina V/uso terapêutico , Pró-Fármacos/uso terapêutico , Cefpodoxima ProxetilRESUMO
Serum lipid and uric acid levels were investigated in two groups of healthy young students. Each member of the control group was given 1 g of citric acid, and each member of the experimental group 4 g of L-ascorbic aicd daily for 4 months. Blood samples were drawn every month and leucocyte ascorbic acid, serum ascorbic acid, cholesterol, free fatty acids, triglycerides and uric acid were determined. The ascorbic acid did not cause dramatic changes in lipid parameters, and no evidence could be found that ascorbic acid raises serum uric acid levels.